Molecular Trigger for VITT Identified

Scientists, primarily led by Flinders University and in collaboration with University of Greifswald and McMaster University, have identified the precise molecular trigger for vaccine-induced immune thrombocytopenia and thrombosis (VITT). This rare blood-clotting disorder was linked to certain adenovirus-based COVID-19 vaccines, such as the Oxford–AstraZeneca COVID-19 vaccine, and in some cases, natural adenovirus infection. The research found that the immune system can mistakenly identify a normal adenovirus protein as platelet factor 4 (PF4), leading to the generation of clotting-activating antibodies. This discovery provides a practical roadmap for vaccine designers to modify or remove this specific adenovirus protein, making future vaccines even safer and more effective, particularly in regions where they are critical tools for disease prevention.